CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Dr Reddys partners with Fujifilm & Global Response Aid for COVID-19 drug
Chinmayee D
/ Categories: Trending, DSIJ News

Dr Reddys partners with Fujifilm & Global Response Aid for COVID-19 drug

Dr Reddy's Laboratories, an integrated pharmaceutical company, announced on Wednesday that it has partnered with Fujifilm Corporation and Global Response Aid (GRA) to develop, manufacture and sell Avigan tablets. 

Avigan tablets with generic name Favipiravir is a potential treatment for COVID-19. Dr Reddy’s has exclusive rights given by Fujifilm to manufacture the drug under the tripartite agreement signed on June 30, 2020. The agreement also grants both Dr Reddy’s and GRA, the right to develop, sell and distribute Avigan in all the countries, except China, Japan and Russia.

Fujifilm is said to receive an upfront licence fee and royalty from the sales by Dr Reddy’s and GRA.

With the pre-clinical and clinical studies data provided by Fujifilm, Dr Reddy’s and GRA will target the regions, where COVID-19 infection has been spreading. Besides, the company is set to receive approval by Fujifilm to use Avigan’s patents of formulation as well as its manufacturing method. It is also in a process to establish a manufacturing setup for the drug with the same quality as of Avigan.

Along with the manufacturing setup, GRA’s global sales network will speed up the supply of drugs in a stable manner. Dr Reddy’s and GRA will introduce the product after all the approvals in their respective countries.

On Wednesday, Dr Reddy’s share is trading at Rs 3,911 with a decline of 0.78 per cent at around 2.25 pm on BSE.

 

Previous Article Fiscal deficit touches 59 per cent of full-year target in May
Next Article Sensex jumps by nearly 500 points; Axis Bank gains by more than 6 per cent; Bajaj Finance remains the volume topper
Print
1149 Rate this article:
5.0
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR